Journal of Neuro-Oncology

, Volume 111, Issue 3, pp 347–353

A phase II trial of oral gimatecan for recurrent glioblastoma

  • Jethro Hu
  • Patrick Y. Wen
  • Lauren E. Abrey
  • Camilo E. Fadul
  • Jan Drappatz
  • Nadia Salem
  • Jeffrey G. Supko
  • Fred Hochberg
Clinical Study

DOI: 10.1007/s11060-012-1023-0

Cite this article as:
Hu, J., Wen, P.Y., Abrey, L.E. et al. J Neurooncol (2013) 111: 347. doi:10.1007/s11060-012-1023-0

Abstract

Gimatecan is a lipophilic oral camptothecin analogue with preclinical activity in glioma models. We conducted a multicenter phase II trial to evaluate the efficacy of gimatecan in adults with recurrent glioblastoma. Eligibility criteria included ≤1 prior treatment for recurrent disease, age ≥18, Eastern Cooperative Oncology Group performance status 0–1, and normal organ function. Patients taking enzyme-inducing anti-seizure medications were excluded. Gimatecan 1.22 mg/m2 was given orally once daily for 5 consecutive days during each 28-day cycle. The primary endpoint was progression-free survival at 6 months. A Simon 2-stage optimal design was used in which 19 patients were evaluated in the 1st stage, with an additional 36 patients accrued if >4 patients in stage 1 achieved PFS at 6 months. 29 patients were enrolled in the study, with median age of 58 years (range, 25–77 years); 58.6 % female. All patients received prior surgery, radiation therapy, and at least one chemotherapy regimen. The daily dose was reduced to 1.0 mg/m2 after four of the first 10 patients experienced grade 4 hematologic toxicity. Treatment-related grade 3/4 toxicities included thrombocytopenia (17.2 %), leukopenia (17.2 %) and neutropenia (10.3 %). None of the 19 patients treated at 1.0 mg/m2/day experienced grade 4 hematologic toxicity. One patient had a partial radiographic response by modified Macdonald criteria. Only 3 patients (12 %) were progression-free at 6 months. Median time to progression was 12.0 weeks (7.0, 17.0).Treatment with gimatecan 1.0 mg/m2/day for 5 days, repeated every 28-days showed minimal efficacy.

Keywords

GimatecanGlioblastomaClinical trialCamptothecinBrain tumorGlioma

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Jethro Hu
    • 1
  • Patrick Y. Wen
    • 2
  • Lauren E. Abrey
    • 3
  • Camilo E. Fadul
    • 4
  • Jan Drappatz
    • 5
  • Nadia Salem
    • 6
  • Jeffrey G. Supko
    • 7
  • Fred Hochberg
    • 8
  1. 1.Johnnie L. Cochran Jr. Brain Tumor CenterLos AngelesUSA
  2. 2.Center For Neuro-Oncology, Dana-Farber Cancer InstituteBostonUSA
  3. 3.Department of Neurology, University of ZurichZurichSwitzerland
  4. 4.Norris Cotton Cancer Center, Dartmouth Hitchcock Medical CenterLebanonUSA
  5. 5.UPMC Cancer PavilionPittsburghUSA
  6. 6.Sigma-Tau Pharmaceuticals Inc.GaithersburgUSA
  7. 7.Clinical Pharmacology LaboratoryMassachusetts General HospitalBostonUSA
  8. 8.Stephen E. & Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonUSA